Copy Link Print Information

MSA-2

35 Cited Publications
Revisión del cliente

Based on 35 publication(s) in Google Scholar

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.81%
  • No. CAS: 129425-81-6
  • Fòrmula: C14H14O5S
  • Peso molecular:294.32
  • Almacenamiento:

    4°C, protect from light

    * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

  • MSA-2 Chemical Structure
    MSA-2 Chemical Structure
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
  • Experimental Validation Results for MSA-2
No. CAS: 129425-81-6
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of MSA-2:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) MSA-2

More
Customer Validation & Images
In Vivo Efficacy StudyFlow CytometryBio/Physico-chemical AssayCell Proliferation/Viability AssayCell Migration/Invasion AssayWB
  • Bio/Physico-chemical Assay
  • Cell Proliferation/Viability Assay
  • Cell Migration/Invasion Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Flow Cytometry
  • In Vivo Efficacy Study
  • WB

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • MSA-2 Chemical Structure
    MSA-2 Chemical Structure
    1/16
  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Apr 11. [Abstract]

    Customer Validation
     MSA-2 (80 mg/kg, orally) strongly affected epithelial cells with a significant decrease in the proportion of Hmga2+ and proliferating epithelial cells.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Feb 6:147:113968. [Abstract]

    Customer Validation
     SN-011 (24, 48, or 72 h) reversed the reduction in cell proliferation caused by PIN1 knockdown in HeLa cells treated with sh-PIN1 or SiHa cells treated with pcDNA-PIN1 and MSA-2 (24, 48, or 72 h).

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Feb 6:147:113968. [Abstract]

    Customer Validation
     Transwell assay demonstrated decreased migratory potential in sh-PIN1-treated HeLa cells, which was partially reversed by SN-011 (24 h) treatment. Conversely, MSA-2 (24 h) reduced the migration of pcDNA-PIN1-treated SiHa cells.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 May 13;42(5):850-868.e9. [Abstract]

    Customer Validation
     Cell viability assays of isogenic NTC, Trp53 KO, and Bak/Bax KO Eμ-Myc lymphoma cell lines treated with S63845 in combination with ADU-S100 (2-10 μg/mL), MSA-2 (12-34 μM), or diABZI for 24 h.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Apr;616(7958):806-813. [Abstract]

    Customer Validation
     Athymic mice were inoculated with 1×105 WT or STING knockout H2087-LCC cells via the tail vein and treated with vehicle or MSA-2 (50 mg/kg; subcutaneous injection) once weekly for 4 weeks starting two weeks after inoculation. Lungs were harvested 6 weeks after inoculation and the number of DTEs were counted.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]

    Customer Validation
     FACS for DC maturation markers. Immature BMDCs were cultured with MSA-2 (0.3-20 μg/mL) for one day and collected for flow cytometry. MSA-2 increased CD80, CD86, H-2Kd (MHC-I), I-A/I-E (MHC-II) dose-dependent.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2022 Oct 8;15(1):142. [Abstract]

    Customer Validation
     The antitumor activity of MSA-2 plus YM101 in murine models. MSA-2 was administrated orally with a single dose of 50 mg/kg. Mice received equivalent mole Ab treatment on alternate days three times.

  • 1/16

    MSA-2 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Oct 24;12(1):17827. [Abstract]

    Customer Validation
     Both diABZI (100 nM) and MSA-2 (25 µM) readily trigger the cleavage of caspase-3 and PARP-1 in monocytes. Low dose of MSA-2 (2.5 µM) and diABZI (100 nM) lead to the cleavage of gasdermin D (an indicator of pyroptosis) in monocytes.

  • MSA-2